By Ahmed Aboulenein WASHINGTON (Reuters) – Most people will retain access to Pfizer’s Paxlovid and Merck’s Lagevrio COVID-19 oral antiviral treatments for little or no cost even after the U.S. …
By Ahmed Aboulenein WASHINGTON (Reuters) – Most people will retain access to Pfizer’s Paxlovid and Merck’s Lagevrio COVID-19 oral antiviral treatments for little or no cost even after the U.S. …